Compare Biogen Inc (BIIB) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance

Biogen IncTrade

Vanguard S&P 500 Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Biogen Inc trades at $191.26 (market cap $28.34B), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.18. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.

	BIIB	VOOG
Market Cap	$28.34B	—
Sector	Health	Broad Market / Factor
52-Week High	$216.63	$85.11
52-Week Low	$122.68	$65.32
Enterprise Value	$30.62B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Vanguard S&P 500 Growth Index Fund ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIIB

Biogen names Michael J. Parini as new Chief Legal Officer starting August 3, 2026GlobeNewsWire · 5 hours agoBullish Real-world study shows 83% of early Alzheimer's patients stable or improved on LEQEMBI over 17 monthsPRNewsWire · 1 day agoBullish Biogen's diranersen shows promising Phase 2 results slowing early Alzheimer's decline and reducing tau protein.GlobeNewsWire · 1 day agoBullish View details →

VOOG

View details →

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

About Vanguard S&P 500 Growth Index Fund ETF

VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.